| | Interview with Peter Kuhn and NPR, Oct 27, 2009 | http://kuhn.scripps.edu/Shared%20Documents/091027-kg-GRANT2.mp3 | | | 11/2/2009 | |
| |
The next Frontiers in Science will take place on October 29 at the Hyatt Regency La Jolla at Aventine. Scripps Research Associate Professor Peter Kuhn will be addressing “Novel Approaches to Monitoring the Spread of Cancer Cells – Finding the Needle in the Haystack to Develop Specialized Treatments.”
He will be joined by a breast cancer survivor who will share her thoughts on his research from the patient’s point of view.
Thursday, October 29, 2009, 6:00–7:00 p.m., Reception to Follow
Hyatt Regency La Jolla at Aventine
3777 La Jolla Village Drive
Seating is limited.
Complimentary self parking available.
The wonder of The Scripps Research Institute multiplies when we’re able to share our passion and excitement about improving health within the community— Feel free to invite a friend or colleague—we look forward to seeing you.
For more information please upload the invitation (PDF): http://kuhn.scripps.edu/Shared%20Documents/Scripps_Inv_v1.pdf
| Frontiers in Science Lectures | | | 10/29/2009 | cancer ctc |
| |
Defining the research plan for the 1st year of 4DB’s Physical-Oncology Center
Thursday OCTOBER 29th and Friday OCTOBER 30th, 2009
Kuhn Laboratory at The Scripps Research Institute
3535 General Atomics Court
San Diego, CA 92121 | | | | 10/29/2009 | |
| |
To see more information about this event please go to
| http://www.asco.org/ASCOv2/Meetings/Breast+Cancer+Symposium | | | 10/8/2009 | ctc, cancer |
| |
PSI-SGKB [doi:10.3942/psi_sgkb/fm_2009_10]
Our cells are filled with a cytoskeleton that provides an infrastructure for support, transport, and locomotion. It is comprised of a network of filaments--actin, intermediate filaments and microtubules--connected by a bewildering variety of receptors, connectors, and motors. Unlike our larger skeleton of bones, however, the cytoskeleton is highly dynamic and is constantly remodeled as the needs of the cell change... | Structure of the Month | | | 10/2/2009 | |
| |
Cambridge Healthech Institute’s Inaugural Circulating Tumor Cells meeting, which is part of ADAPT 2009: Accelerating Development & Advancing Personalized Therapy.
The Inaugural “Circulating Tumor Cells: Shaping the Future of Cancer Care” meeting will cover the following:
• Assay Development for CTC Detection/Analysis
• CTCs as Markers for Disease Prognosis
• Utility of CTCs in Treatment Selection • Cancer Stem Cells
Peter Kuhn will be presenting on Tue, Sept 24th at the CTC Markers section:
"Circulating Tumor Cells as Markers of Disease Progression"
for more information please go to
| Program | | | 9/22/2009 | |
| |
The 7th International Symposium on Minimal Residual Cancer will focus on the technical advancements in the detection and characterization of DTCs and CTCs, and their present use in cancer staging and real time monitoring of systemic anticancer therapies, as well as the specific biological properties and molecular characteristics of these cells. A particular emphasis will be given on the relationship of these cells to cancer stem cells and the relevance of recent findings for the development and use of new targeted therapies in oncology. Our main objective, is to organize a symposium where latest research will be presented by prominent and established researchers in the field and which will bring together and stimulate intense discussions between both basic and clinical researchers in the field.
Peter Kuhn will be presenting on Sat , September 19 at Session V:
"Credentialing of Circulating Tumor Cells - making the connection between the primary and metastatic tumor."
To get more information please visit
| http://www.ismrc2009.org/index1.html | | | 9/16/2009 | |
| |
Aim: To discuss technologies for CTC-based cancer detection, diagnosis, prognosis and treatment; to facilitate new scientific collaborations and interactions; and to build new research programs in the field; to promote the translation of basic research to application/product development.
Peter Kuhn will be presenting on Thursday, September 10,
at Session IV:
"The Physics of the Fluid Biopsy"
Organization: Two-day conference for scientists, engineers, clinicians and investors from academia, medical centers, industry and government. | http://web.ncifcrf.gov/events/tumorcells/default.asp | Preliminary Program >> | | 9/10/2009 | ctc |
| |
Mutations in LOXHD1, an Evolutionarily Conserved Stereociliary Protein, Disrupt Hair Cell Function in Mice and Cause Progressive Hearing Loss in Humans
Nicolas Grillet1, 11, Martin Schwander1, 11, Michael S. Hildebrand2, Anna Sczaniecka1, Anand Kolatkar1, Janice Velasco3, Jennifer A. Webster4, Kimia Kahrizi5, Hossein Najmabadi5, William J. Kimberling6, Dietrich Stephan3, 7, 8, Melanie Bahlo9, Tim Wiltshire10, Lisa M. Tarantino10, Peter Kuhn1, Richard J.H. Smith2 and Ulrich Müller1,
1 Department of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
2 Department of Otolaryngology Head and Neck Surgery, University of Iowa City, IA 55242, USA
3 Genome Institute of the Novartis Research Foundation, San Diego, CA 92121, USA
4 Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
5 Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
6 Department of Genetics, Boys Town National Research Hospital, Omaha, NE 68131, USA
7 Arizona Alzheimer's Consortium, Phoenix, AZ 85004, USA
8 Banner Alzheimer's Institute, Phoenix, AZ 85004, USA
9 Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052 VIC, Australia
10 Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27516, USA
Abstract
Hearing loss is the most common form of sensory impairment in humans and is frequently progressive in nature. Here we link a previously uncharacterized gene to hearing impairment in mice and humans. We show that hearing loss in the ethylnitrosourea (ENU)-induced samba mouse line is caused by a mutation in Loxhd1. LOXHD1 consists entirely of PLAT (polycystin/lipoxygenase/ -toxin) domains and is expressed along the membrane of mature hair cell stereocilia. Stereociliary development is unaffected in samba mice, but hair cell function is perturbed and hair cells eventually degenerate. Based on the studies in mice, we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77, a progressive form of autosomal-recessive nonsyndromic hearing loss (ARNSHL). LOXHD1, MYO3a, and PJVK are the only human genes to date linked to progressive ARNSHL. These three genes are required for hair cell function, suggesting that age-dependent hair cell failure is a common mechanism for progressive ARNSHL. | Abstract | PDF | | 9/4/2009 | |
| |
Archives of Pathology and Laboratory Medicine: Vol. 133, No. 9, pp. 1468–1471.
Circulating Tumor Cells From Well-Differentiated Lung Adenocarcinoma Retain Cytomorphologic Features of Primary Tumor Type
Dena Marrinucci, BS; Kelly Bethel, MD; Madelyn Luttgen, BS; Richard H. Bruce, PhD; Jorge Nieva, MD; Peter Kuhn, PhD
Accepted January 12, 2009
The detailed cytomorphologic appearance of circulating tumor cells (CTCs) in cancer patients is not well described, despite publication of multiple methods for enumerating these cells. In this case study, we present the cytomorphology of CTCs obtained from the blood of a woman with stage IIIB well-differentiated lung adenocarcinoma. Four years after she was diagnosed with her disease, 67 CTCs were identified in a blood sample using an immunofluorescent staining protocol and then subsequently stained with Wright-Giemsa. The cytomorphology of the CTCs was compared with the original tissue biopsy from 4 years prior. We found that CTCs and cells from the original biopsy had strikingly similar morphologic features, including large size in comparison to white blood cells and low nuclear to cytoplasmic ratios with voluminous cytoplasm. Careful cytomorphologic evaluation of CTCs will provide insights about the metastatic significance of these cells, which could yield widespread implications for the diagnosis, treatment, and management of cancer.
| http://arpa.allenpress.com/arpaonline/?request=get-abstract&doi=10.1043/1543-2165-133.9.1468 | | | 9/2/2009 | ctc, cancer |
| |
Professor Peter Kuhn speaks to an enthusiastic audience about his research on novel approaches for monitoring cancer cells. The August 3 talk was part of the Reuben H Fleet Science Center's Senior Mondays program. | http://www.scripps.edu/newsandviews/e_20090810/etc.html | | | 8/10/2009 | cancer cells, ctc |
| |
Postdoctoral positions in translational medicine are available immediately in the Kuhn Laboratory, Cell Biology at TSRI.
For more information please visit
| http://cancer.scripps.edu/joinus.aspx | | | 7/14/2009 | |
| |
The Time Journey and the Force Journey of Cancer Cells | http://www.cmmigranteeconference.org/program.htm | | | 6/22/2009 | |
| |
The phenotype and genotype of circulating tumor cells isolated from the blood of cancer patients.
Circulating tumor cell (CTC) enumeration and characterization have the potential of providing a real-time fluid biopsy which would have widespread implications in the way we currently treat, manage, and even diagnose cancer. Over the past 7 years the Kuhn laboratory has developed an assay to detect CTCs from the blood of cancer patients and has developed new methods and tools to characterize these cells by cytomorphologic and molecular analysis. This laboratory currently has 6 clinical trials ongoing to investigate the incidence and presence of CTCs over time in patients with breast, colorectal, prostate, lung, and pancreatic cancers and how CTC enumeration and characterization correlates with patient response or non-response to treatment. The laboratory is looking for talented graduate students to extend this research to further understand the phenotype and genotype of CTCs in a variety of tumor types as they exist in the blood microenvironment.
| http://kuhn.scripps.edu/contact.aspx | http://cancer.scripps.edu/joinus.aspx | | 5/29/2009 | |
| |
Identification and characterization of malignant melanoma cancer stem cells in the blood of melanoma patients.
The highly qualified postdoctoral fellow will develop an assay to identify and distinguish circulating melanoma cells (CMCs) from the millions of normal cells already present in the blood. This project will be a collaboration between Dr. Peter Kuhn and Dr. Jeanne Loring at Scripps Research, and Dr. Kelly Bethel at Scripps Clinic, who are well-established investigators in rare cell biology, stem cell biology, and hematopathology . The assay will be adapted from an already established circulating tumor cell assay the Kuhn laboratory uses to identify tumor cells in the blood of patients with epithelial cancers. This person will have completed a Ph.D. or MD/PhD on a related topic and preferably a year of postdoctoral research, experience with immunofluorescence staining assays, fluorescent microscopy, fluorescence in-situ hybridization, and mammalian cell culture. Experience with stem cells is also highly desirable. Please see http://cancer.scripps.edu for more information. | http://kuhn.scripps.edu/contact.aspx | http://cancer.scripps.edu/joinus.aspx | | 5/29/2009 | |
| |
Windows HPC Server 2008 (HPC 2008), the latest Microsoft parallel computing package, was specifi cally designed for use in compute-intensive environments, which exactly describes our research laboratory. This article describes the deployment of a wide variety of Microsoft technologies, in particular HPC 2008, in the development of a custom system that enables the automated processing of data generated from an imaging device in a life science laboratory. | | Article | | 4/21/2009 | |
| | A new study shows that monitoring CTCs could be a better predictor than monitoring PSA levels for patients with prostate cancer.
This exciting work was published in The Lancet Oncology. | http://health.usnews.com/articles/health/healthday/2009/02/11/levels-of-circulating-tumor-cells-could-predict.html | | | 2/11/2009 | |
| | Jorge Nieva discusses the lack of funding for lung cancer research | http://www.billingsgazette.net/articles/2008/11/05/features/health/51-lungcancer.txt | | | 1/15/2009 | |
| | What markers should we use to identify CTCs? | http://www.huliq.com/11/75264/prognostic-test-breast-cancer-may-not-detect-all-tumor-types | | | 1/15/2009 | |
| |
Do you want the opportunity to work on an application that promises to help accelerate a cure for cancer?
Microsoft is sponsoring a project to be built by InterKnowlogy for The Scripps Research Institute
InterKnowlogy, experts in Microsoft .NET Tools, Servers and Platforms, is a Microsoft Gold Certified Partner. InterKnowlogy, is a professional services organization specializing in custom application development and network services focused on Microsoft® .NET. Having customers large and small around the world, InterKnowlogy is well known within the .NET ecosystem worldwide as one of the leaders in .NET application development.
The Scripps Research Institute in La Jolla, California, is one of the largest private, nonprofit biomedical research organizations in the US and a world leader in the structure of biological molecules. Scientists at Scripps Research wanted a better way to organize biological research information and share it with their colleagues. InterKnowlogy developed an application built on the Microsoft® .NET Framework 3.0 with Windows® Presentation Foundation, and Windows Vista™ giving scientists a powerful tool to visualize and annotate research results. This application allowed for faster scientific collaboration, easier access to data and a dynamic development process. You can read the full case study on Microsoft.com.
We are embarking on Release II of the application. I have decided to include four developers from the community in the development team (working for Interknowlogy virtually). Here’s what we are looking for in a software development engineer.
- Well-rounded skills in software application development.
- One who has been working primarily with C# for at least the past two years, with an additional minimum three years of Microsoft .NET framework application development experience (and preferable some 2.0 and 3.0 experience).
- Familiarity with Object Oriented design methodology.
- A successful candidate will have experience with Windows client application development (.NET WinForms, preferably WPF) and web services.
- Desirable to have experience with SharePoint, preferable Office SharePoint Server 2007, Office Document XML, or other custom Office applications. You should also have experience working within a distributed development team.
Does this sound like you? Tell me why we should consider you for this opportunity by replying to Calling all Developers with a one-page word document telling us what you are most proud of in your career and why you should be selected to work on this project. Also send us a link to your online presence. We are going to move quickly on this so tell me now why you would be the right person for the team. This is a paid position. And you might even get some publicity for participating! Thanks for considering being a part of this important project!
| Do you want the opportunity to work on an application that promises to help accelerate a cure for cancer? | | | 2/2/2007 | |
| |
Microsoft CEO Steve Ballmer announced business availability of Windows Vista, the 2007 Office system, and Exchange Server 2007 at a press conference in New York City.
During this presentation Tim Huckaby and Peter Kuhn will present C-ME.
| Webcast | | | 11/30/2006 | |
| | California's Scripps Research Institute is one of the first to put the yet-to-be-released operating system to work in a production system.
| Information Week | People and Computers (Hebrew) | | 8/11/2006 | |
| | In the wake of the severe acute respiratory syndrome (SARS)outbreak, an international collaborative effort was developed to investigate the structure of the coronavirus proteome. Groups at the Scripps Research Institute and Tsinghua University solved the structure of the novel SARS coronavirus zinc finger protein nsp10 as both monomer ( Joseph et al.) and dodecamer ( Su et al., p.), while the structure of mouse hepatitis virus nsp15 (a XendoU endoribonuclease) was determined as the active hexamer form and shown to be specific for uridylate ( Xu et al.,). Neuman et al. examined the organization of virions from three different coronaviruses by electron cryomicroscopy, revealing overlapping arrays of structural proteins. Together, these studies provide new insights into the structural basis of coronavirus replication and assembly | | | | 6/10/2006 | |
| | | View Article | | | 6/10/2006 | |
| | | View Article | | | 6/10/2006 | |
| |
Microsoft Forms BioIT Alliance jointly with the Kuhn Lab and other Life Science Industry Leaders to Help Accelerate Pace of Drug Discovery and Development. In addition to this news, the Alliance announces its first project, the Collaborative Molecular Environment (C-ME), a solution for data management to make research more efficient. The first C-ME prototype will be deployed in the Kuhn Lab in Q2 of 2006.
Founding members including Accelrys Software, Affymetrix, Amylin Pharmaceuticals, Applied Biosystems and The Scripps Research Institute share common goal of creating a stronger link between technology and science. | http://www.bioitalliance.org/ | view the Microsoft Press Release | view Forbes PR Newswire | 4/10/2006 | |
| | | | | | 2/10/2006 | |
| | | | News and Views Article in Structure | | 2/10/2006 | |
| |
The Scripps Research Institute and the Palo Alto Research Center realized that by combining their expertise in biological and physical disciplines, they could bring new biomedical breakthrough technologies to translational research. The Scripps-PARC Institute for Advanced Biomedical Sciences was formed in 2002 with the objective of developing new instrumentation and information systems to accelerate discovery in the life sciences.
| PDF | | | 12/10/2005 | |
| | | view article | view article | | 11/10/2005 | |
| | | View Article | | | 8/10/2005 | |
| | | PDF | | | 1/10/2005 | |
| | | PDF | | | 11/10/2004 | |
| | | PDF | | | 4/19/2004 | |
| | | | | | 4/19/2004 | |